Courtney D. DiNardo, MD, on AML: Venetoclax and Azacitidine for Treatment-Naive Patients

July 07, 2020 By The ASCO Post Staff

Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myeloid leukemia who are ineligible for intensive therapy. The research shows venetoclax plus azacitidine improved response rates and overall survival compared with azacitidine alone (Abstract LB2601).

Related Content